Industry

Paula Caplan writes in Psychology Today about ethics complaints which have been filed with the APA (including one by her as an "interested party")...

While there has been a recent push to account for financial conflicts of interest in medical research, less attention has been paid to organizations...

In an interview with Pharmalot, former FDA associate chief counsel Arnie Friede discusses the impact of last month's $181 million Risperdal settlement on pharmaceuticals'...

Sir Robin Murray, a professor at the Institute of Psychiatry, Psychology, and Neuroscience in London, states that he ignored social factors that contribute to ‘schizophrenia’ for too long. He also reports that he neglected the negative effects antipsychotic medication has on the brain.

The warning label for the antidepressant Cymbalta downplayed the risks of withdrawal effects, according to consumer lawsuits being filed in courts across the country. “An estimated 44% to 78% of people who stop taking Cymbalta (also known as duloxetine) will suffer from withdrawal reactions,” yet the warning label “suggests the risk is greater than or equal to 1%.”

The declining number of U.S. medical students choosing psychiatry as a specialty will exacerbate what the A.P.A. already calls a shortage of psychiatrists, according...

A new analysis of the information that the National Institute of Mental Health (NIMH) publishes for parents about attention deficit hyperactivity disorder (ADHD) concludes that the children’s experiences and contexts are ignored and that medication is presented, misleadingly, as the only solution supported by research evidence.

Bloomberg reports that the FDA asked Pfizer in August “to modify safety warnings for its antidepressant Zoloft (sertraline) and acknowledge for the first time that some studies linked the mood-altering medication to heart defects in newborns.”

From ProPublica: Many physicians continue to administer treatments that have long been proven ineffective and even harmful to patients. "For all the truly wondrous developments of modern medicine...

A study published in the Journal of General Internal Medicine asked 1,620 medical students and 739 residents doctors-in-training across the U.S. about their contacts...

“About 30 percent of senators and 20 percent of representatives held assets in biomedical and health-care companies, or in specialty funds set up to invest...

Johnson & Johnson and its subsidiaries will pay more than $2.2 billion - one of the largest health-care fraud settlements in history - to...

In a bellwether case, plaintiffs allege that Pfizer did not adequately warn patients that Zoloft (sertraline) would cause birth defects. The case is scheduled in Federal Court in March, and the verdict will have significant implications for future suits.

Neuroskeptic covers a short article by Susan Lederer that appeared in the American Medical Association Journal of Ethics discussing what happens when research participants die.

British researchers find that a 10% increase in pain medication resulted in a dramatic reduction in the use of antipsychotic and other medications. “When...

Jim Gottstein’s presentation March 29, 2012 at the APA’s Humanistic Division. Mr. Gottstein talks about the the legal and moral issues of the massive number...

Dr. Madhukar Trivedi and colleagues find that the SSRI sertraline does not reduce depressive symptoms any more than placebo in people with Chronic Kidney Disease.

Training for conceptual competence in psychiatry provides a new way forward to address theoretical and philosophical issues in mental health research and practice.

From the New Scientist: “Paul Smaldino and Richard McElreath at the University of California Davis used an evolutionary theory-based computational model to analyse the problem of bad...

A new article in BMJ Evidence-Based Medicine addresses common misinterpretations of the efficacy research on antidepressants.

-ProPublica found a situation where drug companies have a remarkable tendency to frequently misspell their own names and the names of their drugs.

Neuroscience researchers find no differences in brain connectivity between children with diagnoses of autism, ADHD, and those with no diagnoses.

From The New York Times: The Department of Health and Human Services's Office for Human Research Protections recently revised its rules for social science research. Studies...

An article presents new screening tools for pediatric depression and anxiety—but fails to answer its own questions about efficacy.

Behind the U.S. task force recommendation to screen all children and adults for depression.